The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2018;11(2): 28‑38

Read: 3873 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2018;11(2):28‑38. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Uhlig K., Balk E.M., Patel K., et al. Self-Measured Blood Pressure Monitoring: Comparative Effectiveness. Rockville, MD: Agency for Healthcare Research and Quality (U.S.); 2012.
  2. Margolis K.L., Asche S.E., Bergdall A.R., et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA 2013;310:46—56.
  3. McManus R.J., Mant J., Haque M.S., et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA 2014;312:799—808.
  4. Siu A.L. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015;163:778—786.
  5. Yi S.S., Tabaei B.P., Angell S.Y., et al. Self-blood pressure monitoring in an urban, ethnically diverse population: a randomized clinical trial utilizing the electronic health record. Circ Cardiovasc Qual Outcomes 2015;8:138—145.
  6. Agarwal R., Bills J.E., Hecht T.J.W., et al. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 2011;57:29—38.
  7. Pickering T.G., Shimbo D., Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006;354:2368—2374.
  8. Pickering T.G., White W.B., American Society of Hypertension Writing Group. ASH position paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2008;10:850—855.
  9. O’Brien E., Parati G., Stergiou G., et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013;31:1731—1768.
  10. Kikuya M., Hansen T.W., Thijs L., et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007;115:2145—2152.
  11. Niiranen T.J., Asayama K ,Thijs L, et al. Outcome-driven thresholds for home blood pressure measurement: international database of home blood pressure in relation to cardiovascular outcome. Hypertension 2013;61:27—34.
  12. Head G.A., Mihailidou A.S., Duggan K.A., et al. Definition of ambulatory blood pressure targets for diagnosis andtreatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ 2010;340:c1104.
  13. Hansen T.W., Kikuya M, Thijs L., et al. Diagnostic thresholds for ambulatory blood pressure moving lower: areview based on a meta-analysis-clinical implications. J Clin Hypertens (Greenwich) 2008;10:377—381.
  14. Ravenell J., Shimbo D., Booth J.N.3rd, et al. Thresholds for ambulatory blood pressure among African Americans in the Jackson Heart Study. Circulation 2017;135:2470—2480.
  15. Hansen T.W., Kikuya M., Thijs L., et al. Prognostic superiority of day time ambulatory overconventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens 2007;25:1554—1564.
  16. Roush G.C., Fagard R.H., Salles G.F., et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens 2014;32:2332—2340.
  17. Mancia G., Bombelli M., Facchetti R., et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54:226—232.
  18. Ben-Dov I.Z., Ben-Arie L., Mekler J., et al. Reproducibility of white-coat and masked hypertension in ambulatory BP monitoring. Int J Cardiol 2007; 117:355—359.
  19. Bidlingmeyer I., Burnier M., Bidlingmeyer M., et al. Isolated office hypertension: a prehypertensive state? J Hypertens 1996;14:327—332.
  20. Muxfeldt E.S., Fiszman R., de Souza F., et al. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension 2012;59:384—389.
  21. Palatini P., Winnicki M., Santonastaso M., et al. Prevalence and clinical significance of isolated ambulatory hypertension in young subjects screened for stage 1 hypertension. Hypertension 2004;44:170—174.
  22. Trudel X., Milot A., Brisson C. Persistence and progression of masked hypertension: a 5-year prospective study. Int J Hypertens 2013;2013:836387. TAK!
  23. Ugajin T., Hozawa A., Ohkubo T., et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med 2005;165:1541—1546.
  24. Pickering T.G., James G.D., Boddie C., et al. How common is white coat hypertension? JAMA 1988;259:225—228.
  25. Mancia G., Bombelli M., Brambilla G., et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013;62:168—174.
  26. Viera A.J., Hinderliter A.L., Kshirsagar A.V., et al. Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring. Am J Hypertens 2010;23:1190—1197.
  27. Viera A.J., Lin F.-C., Tuttle L.A., et al. Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit 2014;19:208—215.
  28. Ohkubo T., Kikuya M., Metoki H., et al. Prognosis of «masked» hypertension and «white-coat» hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005;46:508—515.
  29. Fagard R.H., Cornelissen V.A. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007;25:2193—2198.
  30. Asayama K., Thijs L., Li Y., et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension 2014;64:935—942.
  31. Pierdomenico S.D., Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 2011;24:52—58.
  32. Stergiou G.S., Asayama K., Thijs L., et al. Prognosis of white-coat and masked hypertension: International Data base of Home Blood Pressure in Relation to Cardiovascular Outcome. Hypertension 2014;63:675—682.
  33. Peacock J., Diaz K.M., Viera A.J., et al. Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens 2014;28:521—528.
  34. Alwan H., Pruijm M., Ponte B., et al. Epidemiology of masked and white-coat hypertension: the family-based SKIPOGH study. PLoS ONE 2014;9:e92522.
  35. Shimbo D., Newman J.D., Schwartz J.E. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens 2012;25:664—671.
  36. Franklin S.S., Thijs L., Asayama K., et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol 2016;68:2033—2043.
  37. Tientcheu D., Ayers C., Das S.R., et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015; 66:2159—2169.
  38. Briasoulis A., Androulakis E., Palla M., et al. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016;34:593—599.
  39. Piper M.A., Evans C.V., Burda B.U., et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015;162:192—204.
  40. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011.
  41. Tomiyama M., Horio T., Yoshii M., et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens 2006;19:880—886.
  42. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403—1419.
  43. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461—470.
  44. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation 2006;113:e463—654.
  45. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266—3281.
  46. Funder J.W., Carey R.M., Mantero F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889—1916.
  47. Pedrosa R.P., Drager L.F., Gonzaga C.C., et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011;58:811—817.
  48. Kump K., Whalen C., Tishler P.V., et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med 1994;150:735—741.
  49. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540—545.
  50. Grossman E., Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012;125:14—22.
  51. Lenders J.W.M., Duh Q.Y., Eisenhofer G., et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915—1942.
  52. Nieman L.K., Biller B.M.K., Findling J.W., et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:1526—1540.
  53. Lurbe E., Cifkova R., Cruickshank J.K., et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009;27:1719—1742.
  54. Berglund G., Andersson O., Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976; 2:554—556.
  55. Hassan-Smith Z., Stewart P.M. Inherited forms of mineralocorticoid hypertension. Curr Opin Endocrinol Diabetes Obes 2011;18:177—185.
  56. Katznelson L., Laws E.R.Jr, Melmed S., et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933—3951.
  57. Selassie A., Wagner C.S., Laken M.L., et al. Progression is accelerated from prehypertension to hypertension in blacks. Hypertension 2011;58:579—587.
  58. Montori V.M., Young W.F. Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002;31:619—632, xi.
  59. Hannemann A., Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies — a review of the current literature. Horm Metab Res 2012;44:157—162.
  60. Rossi G.P., Bernini G., Desideri G., et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006;48:232—238.
  61. Milliez P., Girerd X., Plouin P.-F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243—1248.
  62. Mulatero P., Monticone S., Bertello C., et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013;98:4826—4833.
  63. Rossi G.P., Cesari M., Cuspidi C., et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013;62:62—69.
  64. Fourkiotis V., Vonend O., Diederich S., et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2013;168:75—81.
  65. Cooper C.J., Murphy T.P., Cutlip D.E., et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370:13—22.
  66. Riaz I.B., Husnain M., Riaz H., et al. Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol 2014;114:1116—1123.
  67. Olin J.W., Froehlich J., Gu X., et al. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 2012;125: 3182—3190.
  68. Trinquart L., Mounier-Vehier C., Sapoval M., et al. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension 2010;56:525—532.
  69. Neter J.E., Stam B.E., Kok F.J., et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42:878—884.
  70. Whelton P.K., Kumanyika S.K., Cook N.R., et al. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr 1997;65:652S—60S.
  71. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992;267:1213—1220.
  72. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997;157:657—667.
  73. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3—10.
  74. Appel L.J., Champagne C.M., Harsha D.W., et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003;289:2083—2093.
  75. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117—1124.
  76. Mozaffarian D., Fahimi S., Singh G.M., et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014;371:624—634.
  77. Aburto N.J., Ziolkovska A., Hooper L., et al. Effect of lower sodium intake on health: systematic review and meta- analyses. BMJ 2013;346:f1326.
  78. He F.J., Li J., MacGregor G.A. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ 2013;346:f1325.
  79. Graudal N.A., Hubeck-Graudal T., Jurgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 2012;25:1—15.
  80. Whelton P.K., Appel L.J., Espeland M.A., et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998;279:839—846.
  81. Whelton P.K., He J., Cutler J.A., et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997;277: 1624—1632.
  82. Geleijnse J.M., Kok F.J., Grobbee D.E. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 2003;17:471—480.
  83. World Health Organization. Guideline: Potassium Intake for Adults and Children. Geneva, Switzerland: World Health Organization; 2012.
  84. Whelton P.K., He J. Health effects of sodium and potassium in humans. Curr Opin Lipidol 2014;25:75—79.
  85. Aburto N.J., Hanson S., Gutierrez H., et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013;346:f1378.
  86. Cornelissen V.A., Smart N.A. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc 2013;2:e004473.
  87. Carlson D.J., Dieberg G., Hess N.C., et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis. Mayo Clin Proc 2014;89:327—334.
  88. Garcia-Hermoso A., Saavedra J.M., Escalante Y. Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials. Obes Rev 2013;14:919—928.
  89. Rossi A.M., Moullec G., Lavoie K.L., et al. The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example. Can J Cardiol 2013;29:622—627.
  90. Whelton S.P., Chin A., Xin X., et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002;136:493—503.
  91. Xin X., He J., Frontini M.G., et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38: 1112—1117.
  92. Roerecke M., Kaczorowski J., Tobe S.W., et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2017;2:e108—120.
  93. Stewart S.H., Latham P.K., Miller P.M., et al. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction 2008;103:1622—1628.
  94. Dickinson H.O., Mason J.M., Nicolson D.J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006;24:215—233.
  95. Wallace P., Cutler S., Haines A. Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption. BMJ 1988;297:663—668.
  96. Lang T., Nicaud V., Darne B., et al. Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group. J Epidemiol Community Health 1995;49:610—616.
  97. Chang A.R., Sang Y., Leddy J., et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 2016; 67:1181—1188.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.